Holen Sie sich die Stockscreener-App
114.24
1.49%
1.68
Handel nachbörslich:
114.58
0.34
+0.30%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$112.56
Offen:
$112.56
24-Stunden-Volumen:
7.45M
Relative Volume:
0.78
Marktkapitalisierung:
$282.15B
Einnahmen:
$65.51B
Nettoeinkommen (Verlust:
$8.93B
KGV:
32.15
EPS:
3.5532
Netto-Cashflow:
$14.12B
1W Leistung:
+1.66%
1M Leistung:
-4.06%
6M Leistung:
+20.19%
1J Leistung:
+47.92%
1-Tages-Spanne:
$112.13
$115.10
1-Wochen-Bereich:
$110.94
$115.10
52-Wochen-Spanne:
$75.40
$125.14
Merck Co Inc Stock (MRK) Company Profile
Firmenname
Merck Co Inc
Sektor
Telefon
908-740-4000
Adresse
126 EAST LINCOLN AVENUE, RAHWAY, NJ
Compare MRK vs LLY, JNJ, ABBV, NVS, AZN
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MRK
Merck Co Inc
|
114.24 | 278.00B | 65.51B | 8.93B | 14.12B | 3.5532 |
LLY
Lilly Eli Co
|
1,021.41 | 881.12B | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
230.00 | 551.06B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
213.76 | 369.98B | 62.82B | 3.60B | 19.98B | 2.0274 |
NVS
Novartis Ag Adr
|
150.44 | 284.59B | 54.66B | 13.58B | 16.05B | 7.0171 |
AZN
Astrazeneca Plc
|
184.64 | 285.23B | 60.48B | 10.40B | 8.05B | 3.3297 |
Merck Co Inc Stock (MRK) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-25 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2026-02-20 | Eingeleitet | Barclays | Overweight |
| 2026-02-13 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2026-01-08 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2025-12-18 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2025-11-24 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2025-11-13 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-10-13 | Fortgesetzt | Citigroup | Neutral |
| 2025-09-17 | Herabstufung | Berenberg | Buy → Hold |
| 2025-05-14 | Herabstufung | Citigroup | Buy → Neutral |
| 2025-04-22 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2025-02-18 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2025-02-10 | Herabstufung | TD Cowen | Buy → Hold |
| 2025-01-08 | Herabstufung | Truist | Buy → Hold |
| 2024-12-20 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2024-12-10 | Fortgesetzt | BofA Securities | Buy |
| 2024-12-04 | Hochstufung | HSBC Securities | Hold → Buy |
| 2024-11-15 | Eingeleitet | Wolfe Research | Peer Perform |
| 2024-11-11 | Herabstufung | Daiwa Securities | Buy → Neutral |
| 2024-10-17 | Eingeleitet | Bernstein | Mkt Perform |
| 2024-03-11 | Herabstufung | Societe Generale | Hold → Sell |
| 2024-01-04 | Hochstufung | TD Cowen | Market Perform → Outperform |
| 2023-11-09 | Eingeleitet | Deutsche Bank | Buy |
| 2023-10-27 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2023-10-20 | Hochstufung | UBS | Neutral → Buy |
| 2023-07-14 | Eingeleitet | HSBC Securities | Hold |
| 2023-04-13 | Hochstufung | Citigroup | Neutral → Buy |
| 2023-03-28 | Herabstufung | Societe Generale | Buy → Hold |
| 2023-03-13 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-03-06 | Eingeleitet | Jefferies | Buy |
| 2023-02-22 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2023-01-04 | Hochstufung | BofA Securities | Neutral → Buy |
| 2022-11-18 | Eingeleitet | Credit Suisse | Outperform |
| 2022-10-10 | Hochstufung | Guggenheim | Neutral → Buy |
| 2022-09-14 | Hochstufung | Berenberg | Hold → Buy |
| 2022-07-06 | Hochstufung | Daiwa Securities | Neutral → Buy |
| 2022-06-06 | Fortgesetzt | SVB Leerink | Outperform |
| 2022-04-06 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2021-12-17 | Eingeleitet | Goldman | Buy |
| 2021-12-16 | Eingeleitet | Daiwa Securities | Neutral |
| 2021-12-13 | Herabstufung | UBS | Buy → Neutral |
| 2021-12-09 | Eingeleitet | Wells Fargo | Overweight |
| 2021-12-07 | Herabstufung | Guggenheim | Buy → Neutral |
| 2021-11-29 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2021-11-01 | Hochstufung | Argus | Hold → Buy |
| 2021-09-07 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-07-27 | Fortgesetzt | Truist | Buy |
| 2021-05-20 | Herabstufung | Argus | Buy → Hold |
| 2021-04-07 | Fortgesetzt | RBC Capital Mkts | Sector Perform |
| 2020-11-10 | Fortgesetzt | Bernstein | Outperform |
| 2020-09-29 | Eingeleitet | Berenberg | Hold |
| 2020-08-03 | Hochstufung | Goldman | Neutral → Buy |
| 2020-06-12 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2020-02-27 | Eingeleitet | Barclays | Overweight |
| 2020-01-07 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2019-10-17 | Fortgesetzt | BofA/Merrill | Neutral |
| 2019-08-16 | Eingeleitet | SVB Leerink | Outperform |
| 2019-07-03 | Eingeleitet | Mizuho | Buy |
| 2019-05-28 | Eingeleitet | Goldman | Neutral |
| 2019-05-13 | Hochstufung | Atlantic Equities | Neutral → Overweight |
| 2018-10-16 | Bestätigt | Citigroup | Buy |
| 2018-10-09 | Fortgesetzt | Guggenheim | Buy |
| 2018-04-23 | Hochstufung | Goldman | Neutral → Buy |
| 2018-04-17 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2018-04-05 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2018-03-12 | Hochstufung | Leerink Partners | Mkt Perform → Outperform |
| 2018-02-14 | Bestätigt | Leerink Partners | Mkt Perform |
| 2018-02-07 | Bestätigt | Morgan Stanley | Equal-Weight |
| 2018-01-16 | Hochstufung | SunTrust | Hold → Buy |
Alle ansehen
Merck Co Inc Aktie (MRK) Neueste Nachrichten
Merck & Co. Inc. stock (US58933Y1055): Key takeaways after latest Keytruda data and oncology updates - AD HOC NEWS
Oorja Bio Launches as a Clinical-Stage Company to Develop Groundbreaking Therapies for Idiopathic Pulmonary Fibrosis (IPF) and Other Fibrotic Diseases - GlobeNewswire Inc.
Merck & Co Inc (MRK) Stock Price, Trades & News - GuruFocus
Merck & Co., Inc. stock (US58933Y1055): Key takeaways after the latest Keytruda and Gardasil updates - AD HOC NEWS
Handelsbanken Fonder AB Boosts Stock Holdings in Merck & Co., Inc. $MRK - MarketBeat
Gabelli Funds LLC Cuts Holdings in Merck & Co., Inc. $MRK - MarketBeat
HighTower Advisors LLC Sells 50,990 Shares of Merck & Co., Inc. $MRK - MarketBeat
Merck & Co., Inc. Trade Ideas — LSX:A0YD8Q - TradingView
Merck & Co. Inc. stock (US58933Y1055): Terns deal, oncology pipeline keep focus on growth - AD HOC NEWS
MRK Stock Quote Price and Forecast - cnn.com
Merck & Co. Inc. stock (US58933Y1055): oncology growth meets new M&A financing - AD HOC NEWS
Merck's drug helps uterine cancer patients live longer in late-stage trial - Reuters
Merck Announces TroFuse-005 Trial Evaluating Sacituzumab Tirumotecan (Sac-TMT) Met Primary Endpoints of Overall Survival (OS) and Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer - Business Wire
Merck & Company, Inc. (MRK) Stock Analysis: A Healthcare Giant with a Robust 3.05% Dividend Yield - DirectorsTalk Interviews
L & S Advisors Inc Increases Stake in Merck & Co., Inc. $MRK - MarketBeat
Canada Post Corp Registered Pension Plan Acquires 35,631 Shares of Merck & Co., Inc. $MRK - MarketBeat
Merck & Co., Inc. stock (US58933Y1055): Keytruda momentum and fresh earnings keep big pharma in focu - AD HOC NEWS
Financial Security Advisor Inc. Raises Holdings in Merck & Co., Inc. $MRK - MarketBeat
Lockheed Martin Investment Management Co. Has $9.87 Million Stock Holdings in Merck & Co., Inc. $MRK - MarketBeat
Merck & Co., Inc. $MRK Shares Acquired by Convergence Investment Partners LLC - MarketBeat
Merck & Co., Inc. $MRK Stake Reduced by ANTIPODES PARTNERS Ltd - MarketBeat
Merck & Co. Inc. stock underperforms Friday when compared to competitors - MarketWatch
Merck & Co. Inc. stock (US58933Y1055): Key cancer franchise drives fresh earnings spotlight - AD HOC NEWS
Merck & Co., Inc. stock (US58933Y1055): pharma giant doubles down on M&A as investors eye post-Keytr - AD HOC NEWS
Merck & Co., Inc. $MRK Stock Holdings Increased by Phoenix Financial Ltd. - MarketBeat
Merck & Co., Inc. $MRK is Conning Inc.'s 5th Largest Position - MarketBeat
Bessemer Group Inc. Increases Holdings in Merck & Co., Inc. $MRK - MarketBeat
Allworth Financial LP Grows Stake in Merck & Co., Inc. $MRK - MarketBeat
Merck & Co., Inc.: Target Price Consensus and Analysts Recommendations | MRK | US58933Y1055 - marketscreener.com
Mondrian Global Equity Value Fund's Merck & Co Inc(MRK) Holding History - GuruFocus
Horizon Dividend Income ETF's Merck & Co Inc(MRK) Holding History - GuruFocus
Merck & Co., Inc. stock (US58933Y1055): Latest developments and business overview - AD HOC NEWS
Merck & Co. Inc. stock (US58933Y1055): Latest developments and business overview - AD HOC NEWS
Merck & Co., Inc. (MRK) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
World Investment Advisors Buys 20,067 Shares of Merck & Co., Inc. $MRK - MarketBeat
Rayburn West Financial Services LLC Takes $1.17 Million Position in Merck & Co., Inc. $MRK - MarketBeat
Summit Wealth Group LLC Co. Has $522,000 Stock Position in Merck & Co., Inc. $MRK - MarketBeat
Bank Julius Baer & Co. Ltd Zurich Buys 100,280 Shares of Merck & Co., Inc. $MRK - MarketBeat
Top Companies in Hospital Acquired Infection Treatment MarketMerck & Co Inc, Pfizer Inc, Cipla Ltd etc. - openPR.com
Merck & Co. Inc. stock (US58933Y1055): Q1 results show revenue growth amid Keytruda strength - AD HOC NEWS
Merck & Co., Inc. stock (US58933Y1055): Q1 beat and upgraded 2026 guidance drive 8% jump - AD HOC NEWS
Merck & Co. Inc. stock (US58933Y1055): Q1 earnings beat with revenue growth - AD HOC NEWS
Merck's (NYSE:MRK) Soft Earnings Are Actually Better Than They Appear - Moomoo
VIRGINIA RETIREMENT SYSTEMS ET Al Reduces Position in Merck & Co., Inc. $MRK - MarketBeat
Merck & Co., Inc. $MRK Stake Lifted by Independent Advisor Alliance - MarketBeat
Merck & Co., Inc. $MRK Shares Sold by Money Concepts Capital Corp - MarketBeat
Merck & Co., Inc. (MRK) 10K Form and Latest SEC Filings 2026 - MarketBeat
Analyst Reinstates Merck (MRK) with ‘Neutral’ Rating, $125 Price Target - Insider Monkey
Merck & Co. stock (US58933Y1055): Oncology portfolio advances at ASCO 2026 - AD HOC NEWS
The Zacks Analyst Blog UnitedHealth, Merck & Co., Qualcomm, EVI and Optex - Zacks Investment Research
Merck (MRK) Tops Quarterly Sales Forecasts as Keytruda Drives Growth - Insider Monkey
Finanzdaten der Merck Co Inc-Aktie (MRK)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.39%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):